Dexlansoprazole, a proton pump inhibitor drug, is utilized for treating erosive esophagitis and non-erosive reflux diseases. This study was conducted to explore the impact of dexlansoprazole on stomach ulcers caused by piroxicam in male Albino rats. Fifty adult rats were classified into five groups of ten each. The first group was not given any medication and received only saline, serving as control negative. Groups 2,3,4, and 5 received piroxicam (PXE) 30 mg/kg b wt. once daily for three days in a row via oral route, with the second group remaining untreated and kept as a positive control. The third group of rats was given omeprazole (OMP) 0.36 mg/kg b wt., and the fourth group was given dexlansoprazole (DXL) 0.6 mg/kg b wt. The rats in the fifth group received DXL at a dose of 1.2 mg/kg b wt. For 21 days in a row, groups 3, 4, and 5 received their medications orally once daily. Finally, rats were put to sleep and their blood was taken to measure serum AST, ALT, ALP, urea, creatinine, uric acid, serum potassium, magnesium, phosphorus and calcium. The stomach was isolated and evaluated for ulcer index, ulcer score and preventive index. A part of the stomach was prepared for tissue homogenate, while another part of the stomach and liver was utilized for histopathology. Piroxicam administration resulted in marked elevation in the gastric ulcer index, ulcer score, liver function tests, and gastric Malondialdehyde were significantly increased while gastric catalase, Super oxide dismutase, and glutathione peroxidase were significantly decreased, along with histopathological alterations were found in stomach and hepatic tissues. Treatment with either OMP or DXL elicited significant improvement in the aforementioned parameters. From the obtained results, it could be concluded that both omeprazole and dexlansoprazole are potent and effective medications for treating gastric damage caused by piroxicam, with dexlansoprazole was less superior than omeprazole but with minor adverse events on serum minerals.